- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: covid-19 and sarilumab.
Displaying page 1 of 1.
EudraCT Number: 2020-001390-76 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patie... | |||||||||||||
Medical condition: Covid-19 coronavirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001745-40 | Sponsor Protocol Number: COVID-SARI-001 | Start Date*: 2020-04-23 | |||||||||||
Sponsor Name:ASST FATEBENEFRATELLI SACCO | |||||||||||||
Full Title: PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION | |||||||||||||
Medical condition: Patients with COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002037-15 | Sponsor Protocol Number: SARTRE | Start Date*: 2020-05-25 |
Sponsor Name:Cristina Avendaño Sola | ||
Full Title: Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients | ||
Medical condition: SARS-CoV-2 infected patients with pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001634-36 | Sponsor Protocol Number: SARCOVID | Start Date*: 2020-04-09 |
Sponsor Name:Rosario García de Vicuña | ||
Full Title: Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection. | ||
Medical condition: COVID-19 infection requiring hospitalization | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001255-40 | Sponsor Protocol Number: STRIKE-SARS-CoV2 | Start Date*: 2020-04-16 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19. | |||||||||||||
Medical condition: Severe pneumonia caused by infection with SARS CoV 2. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001162-12 | Sponsor Protocol Number: EFC16844 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:Sanofi-aventis Recherche et Développement | |||||||||||||
Full Title: An adaptive phase 3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 | |||||||||||||
Medical condition: Corona virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001290-74 | Sponsor Protocol Number: SARICOVID | Start Date*: 2020-04-11 | |||||||||||
Sponsor Name:Consorci Parc de Salut Mar (PSMAR) | |||||||||||||
Full Title: Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care | |||||||||||||
Medical condition: Patients with confirmed COVID-19 infection and criteria for mild-moderate pneumonia (CURB-65 ≤1 i SatO2 ≥90%, MEWS score less than 3) and IL6 values of 20 pg / ml, will be randomly assigned to a sa... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001531-27 | Sponsor Protocol Number: SARICOR | Start Date*: 2020-04-18 | ||||||||||||||||
Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
Full Title: Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome | ||||||||||||||||||
Medical condition: SARS-CoV-2 infection causing respiratory disease and cytokine release syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001367-88 | Sponsor Protocol Number: 25032020 | Start Date*: 2020-04-14 | |||||||||||
Sponsor Name:Department of Infectious diseases | |||||||||||||
Full Title: Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial ... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001854-23 | Sponsor Protocol Number: AMMURAVID | Start Date*: 2020-04-27 |
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | ||
Full Title: Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001357-52 | Sponsor Protocol Number: EnCovid-hidroxiCLOROQUINA | Start Date*: 2020-05-13 | |||||||||||
Sponsor Name:IDIVAL | |||||||||||||
Full Title: Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in... | |||||||||||||
Medical condition: Quimioprophylaxis of SARS-CoV-2 infection with hydroxyloquine (HCQ) in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or J... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001275-32 | Sponsor Protocol Number: APPI2-CV-2020-01 | Start Date*: 2020-04-03 | |||||||||||
Sponsor Name:The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark | |||||||||||||
Full Title: Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001246-18 | Sponsor Protocol Number: APHP200375 | Start Date*: 2020-03-25 |
Sponsor Name:Assistance Publique - Hôpitaux de Paris | ||
Full Title: Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002340-14 | Sponsor Protocol Number: REMAP-CAP | Start Date*: 2015-09-16 | ||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||
Full Title: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19) | ||||||||||||||||||
Medical condition: Severe Community Acquired Pneumonia COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) IE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Ongoing) BE (Trial now transitioned) DE (Ongoing) HR (Ongoing) ES (Temporarily Halted) FR (Trial now transitioned) FI (Ongoing) IT (Ongoing) CZ (Trial now transitioned) SI (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000169-42 | Sponsor Protocol Number: KPL-404-C211 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Kiniksa Pharmaceuticals, Ltd. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Art... | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Ongoing) HU (Ongoing) BG (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.